EGFR and non-small cell lung carcinoma: Interestingly, the pyruvate dehydrogenase kinase inhibitors (PDK inhibitors) used in all of the studies looking into combination therapy including EGFR-TKIs and PDK inhibitors to overcome resistance in NSCLC were synthetic.